Participants
medication-refractory, primary RLS
RESTFUL study completers were eligible unless they failed to comply with RESTFUL study instructions or developed a new contraindication to TOMAC. The RESTFUL study enrolled individuals aged 22–79 years with medication-refractory moderate-to-severe primary RLS. Consistent with the most recent expert consensus definition [